James Tumlin, MD
Nephrology · Lawrenceville, GANPI 1467418053
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.3%. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $753.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$97K
- Calliditas Therapeutics US Inc.$67K
- Travere Therapeutics, Inc.$53K
- AstraZeneca$52K
- Otsuka America Pharmaceutical, Inc.$35K
- Bayer$34K
- plus $96K from 28 others
Across 832 payments — averaging $23,253 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$10.1M
- Novartis$4.5M
- Mallinckrodt Hospital Products Inc.$1.6M
- Vertex$1.2M
- Akebia Therapeutics Inc$407K
- Genentech, Inc.$367K
- plus $1.2M from 16 others
What the payments were for
- Consulting fees$117,04127%
- Speaking & faculty fees$241,52756%
- Travel & lodging$57,45813%
- Food & beverage$17,0264%
- Education$8040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 118 | $96,723 |
| Calliditas Therapeutics US Inc. | 67 | $67,041 |
| Travere Therapeutics, Inc. | 62 | $53,048 |
| AstraZeneca(2 entities) | 89 | $52,120 |
| Otsuka America Pharmaceutical, Inc. | 19 | $35,343 |
| Bayer | 36 | $33,825 |
| Mallinckrodt Hospital Products Inc. | 43 | $28,457 |
| Mallinckrodt Enterprises LLC | 24 | $27,183 |
| La Jolla Pharmaceutical Company | 8 | $9,359 |
| Amgen(2 entities) | 25 | $9,339 |
| Vifor Pharma, Inc. | 12 | $6,496 |
| Argenx US, Inc. | 2 | $3,750 |
| Akebia Therapeutics Inc | 4 | $2,864 |
| Apellis Pharmaceuticals, Inc. | 5 | $2,328 |
| Novartis | 20 | $1,981 |
| Astrazeneca UK Limited | 1 | $1,459 |
| Omeros Corporation | 2 | $832 |
| Pfizer | 4 | $593 |
| GSK | 12 | $294 |
| Vertex | 4 | $222 |
| Outset Medical Inc | 1 | $125 |
| Genentech, Inc. | 1 | $82 |
| Alnylam Pharmaceuticals Inc. | 4 | $72 |
| Mozarc Medical US LLC | 1 | $68 |
| Shire North American Group Inc | 1 | $56 |
| Sanofi | 2 | $43 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $38 |
| Ardelyx, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
| Fresenius USA Marketing, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$433,856 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 11 | $665,860 |
| FarxigaDapagliflozin Propanediol | 41 | $40,797 |
| Tacrolimus | 36 | $3,705 |
| Eplerenone | 29 | $1,962 |
| Diltiazem Hcl | 18 | $834 |
| Nifedipine ErNifedipine | 20 | $792 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $529 |
| Allopurinol | 48 | $313 |
| Furosemide | 63 | $274 |
| Lisinopril | 32 | $234 |
| Losartan Potassium | 20 | $206 |
| Calcitriol | 21 | $153 |
| Atorvastatin Calcium | 21 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris, Farxiga | $52,120 | $706,65752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Lawrenceville
- William PaxtonLawrenceville$73K
- Sharad VirmaniLawrenceville$55K
- Lorin SanchezLawrenceville$23K
- Aakash AminLawrenceville$22K
- Kathryn ElmoreLawrenceville$12K
- Shaun ConlonLawrenceville$11K
- Nnamdi NwaohiriLawrenceville$11K
- Jusong ChoiLawrenceville$8K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.